期刊文献+

HPLC荧光法测定人血浆中的5-氨基水杨酸

Determination of 5-aminosalicylic acid in human plasma by HPLC-FLU
原文传递
导出
摘要 目的采用HPLC荧光法测定人血浆中的5-氨基水杨酸,研究单剂量口服柳氮磺吡啶肠溶片后5-氨基水杨酸在中国健康受试者体内的药动学特征。方法 24名健康受试者口服500 mg柳氮磺吡啶肠溶片,采用HPLC荧光法测定血浆中5-氨基水杨酸的浓度,利用DAS 2.1.1软件计算药动学参数。结果 5.055~808.8 ng.mL-15-氨基水杨酸与峰面积比值的线性关系良好(r=0.9985),最低检测浓度为5.055 ng.mL-1,日内、日间RSD均<10%。单次口服给药后,药动学参数为:t1/2=11.19±2.48 h,Cmax=232.83±57.94 ng.mL-1,Tmax=17.58±5.33 h,AUC(0~t)=5.5907±1.7848μg.h.mL-1。结论所用方法准确、灵敏度高、重复性好,可用于口服柳氮磺吡啶肠溶片后5-氨基水杨酸血药浓度测定及人体药动学研究。 OBJECTIVE To establish an HPLC-fluoresence method for the determination of 5-aminosalicylic acid in human plas-ma and study the pharmacokinetics in Chinese healthy volunteers following oral administration of sulfasalazine enteric-oated tablets. METHODS In the study,24 volunteers were administered with single oral dose of 500 mg of sulfasalazine enteric-coated tablets. The plasma concentrations of 5-aminosalicylic acid was determined by HPLC-fluoresence method.The pharmacokinetic parameters were calculated with aid of the software DAS 2.1.1.RESULTS The calibration curve of 5-aminosalicylic acid was linear in the range from 5.055 to 808.8 ng·mL-1 (r=0.9985).The lowest limit of quantification of 5-aminosalicylic acid was 5.055 ng·mL-1. Both the intra-day and inter-day RSD were less than 10%.The main pharmacokinetic parameters of 5-aminosalicylic acid were as follows:t 1/2 was 11.19±2.48 h,C max was 232.83±57.94 ng·mL-1 ,T max was 17.58±5.33 h and AUC(0~t)was 5.5907±1.7848μg· h·mL-1 .CONCLUSION The HPLC-fluoresence method is precise,sensitive and reproducible.It can be used in the determination of 5-aminosalicylic acid in human plasma and clinical pharmacokinetics studies following oral administration of sulfasalazine enteric-coated tablets.
出处 《华西药学杂志》 CAS CSCD 北大核心 2013年第4期409-411,共3页 West China Journal of Pharmaceutical Sciences
关键词 5-氨基水杨酸 高效液相色谱荧光法 药动学 柳氮磺吡啶肠溶片 5-Aminosalicylic acid HPLC-fluoresence Pharmacokinetics Sulfasalazine enteric-coated tablets
  • 相关文献

参考文献5

  • 1杜凯阳,肖征宇.柳氮磺吡啶治疗类风湿关节炎研究进展[J].中国药物与临床,2008,8(6):480-482. 被引量:9
  • 2Nobilis M, Vybiralova Z, Sladkova K, et al. High performance liq- uid chromatographic determination of 5 -aminosalicylic acid and its metabolites in blood plasma [ J]. J Chromatogr A ,2006,1119 : 299 - 308.
  • 3Pastorini E, Locatelli M, Simonib P, et al. Development and vali- dation of a HPLC - ESI - MS/MS method for the determination of 5 - aminosalicylic acid and its major metabolite N - acetyl - 5 - aminosalicylic acid in human plasma[ J ]. J Chromatogr B, 2008, 872,99 - 106.
  • 4Gu GZ, Xia HM, Pang ZQ, et al. Determination of sulphasalazine and its main metabolite sulphapyridine and 5 - aminosalicylic acid in human plasma by liquid chromategraphy/tandem mass spectrometry and its application to a pharmacokinetic study[ J]. J Chromatogr B ,2011,879:449 - 456.
  • 5Ma JJ, Liu CG, Li JH, et al. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population[ J]. Clin Chim Ac- ta,2009,407 : 30 - 35.

二级参考文献24

  • 1Plosker GL, Croom KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs,2005,65 (13):1825- 1849.
  • 2Haagsma C J, Russel FG, Vree TB, et al. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to cliuical response. Br J Clin Pharmacol, 1996,42(2): 195-200.
  • 3Jansen G, Van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum, 2004,50(7):2130-2139.
  • 4Gadangi P, Longaker M, Naime D, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol, 1996,156(5):1937-1941.
  • 5Danning CL, Boumpas DT. Commonly used disease-modifying antirheumatic drugs in the treatment of inflammatory arthritis: an update on mechanisms of action. Clin Exp Rheumatol, 1998,16 (5):595-604.
  • 6Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest, 1998, 101(5):1163-1174.
  • 7Volin MV, Harlow LA, Woods JM, et al. Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis Rheum, 1999,42(9):1927-1935.
  • 8Lee CK, Lee EY, Chung SM, et al. Effects of disease-modifying antirheurnatic drags and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappa B, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum,2004,50 (12): 3831-3843.
  • 9Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet,1999,353(9149):259-266.
  • 10Combe B, Codreanu C, Fiocco U, et al, Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis,2006,65(10):1357-1362.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部